Provider: ValuEngine, Inc.
Innate Pharma SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Innate Pharma SA Announces New Preclinical Data on Lirilumab
Innate Pharma SA announced new preclinical results from research conducted by Dr Holbrook Kohrt from Stanford University, Innate Pharma and CIML1 on Lirilumab. They support the monotherapy activity of lirilumab in mouse models of lymphoma, through the enhancement of NK cell cytotoxicity. Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab, lirilumab enhanced NK cell-mediated, antibody-dependent cellular cytotoxicity (ADCC) against lymphoma in vitro and in vivo in mouse models. Taken together, these data reinforce the rationale for the development of lirilumab in onco-hematology, and open new perspectives for the combination of lirilumab with antibody drugs active through ADCC.
Latest Key Developments in Biotechnology
- Quest PharmaTech Inc signs license agreement with Bioceltran Co., Ltd. for Photodynamic Therapy Technology
- Calithera Biosciences Inc announces pricing of initial public offering
- Eleven Biotherapeutics Inc announces top-line results from phase 2 study of EBI-005 in patients with moderate to severe allergic conjunctivitis
- Biofrontera AG says Ameluz studies confirm efficacy and safety
- Share this
- Digg this